Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Alector ( (ALEC) ) has provided an announcement.
Alector, Inc. is implementing a 17% workforce reduction to align with strategic priorities after its INVOKE-2 trial of AL002 in early Alzheimer’s disease did not meet primary endpoints. Despite these setbacks, Alector remains committed to advancing its drug candidates for neurodegenerative diseases and expects its cash reserves to fund operations through 2026. The company continues to develop its Alector Brain Carrier platform and other promising therapies, aiming to improve patient outcomes with innovative treatments.
Learn more about ALEC stock on TipRanks’ Stock Analysis page.
